Premier Path Wealth Partners’s Arbutus Biopharma ABUS Stock Holding History

Premier Path Wealth Partners’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$180K	Hold	40,000	–	–	0.02%	395
2025 Q4	$192K	Hold	40,000	–	–	0.02%	391
2025 Q3	$182K	Hold	40,000	–	–	0.02%	389
2025 Q2	$124K	Hold	40,000	–	–	0.02%	385
2025 Q1	$140K	Hold	40,000	–	–	0.02%	369
2024 Q4	$131K	Hold	40,000	–	–	0.02%	369
2024 Q3	$154K	Buy	40,000 +4,000	+11%	+$15.3K	0.02%	361
2024 Q2	$111K	Buy	36,000 +5,500	+18%	+$16.5K	0.02%	366
2024 Q1	$78.7K	Buy	30,500 +8,300	+37%	+$21.5K	0.01%	341
2023 Q4	$55.5K	Buy	+22,200	New	+$43.5K	0.01%	332

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Premier Path Wealth Partners's ABUS Position: Q1 2026 in Review

Premier Path Wealth Partners held its Arbutus Biopharma (ABUS) position steady in Q1 2026 at 40,000 shares worth $180K. The position accounts for 0.02% of the portfolio, ranked #395.

Premier Path Wealth Partners first reported a position in ABUS in Q4 2023 and has held it in 10 quarters since. The position peaked at $192K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Premier Path Wealth Partners held 40,000 shares of Arbutus Biopharma worth $180K as of Q1 2026.
Premier Path Wealth Partners left its Arbutus Biopharma share count unchanged in Q1 2026.
Arbutus Biopharma made up 0.02% of Premier Path Wealth Partners's portfolio in Q1 2026, its #395 holding.
Premier Path Wealth Partners first reported a position in Arbutus Biopharma in Q4 2023 and has held it in 10 quarters since.
Premier Path Wealth Partners's Arbutus Biopharma position peaked at $192K in Q4 2025.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Premier Path Wealth Partners's 13F filing for Q1 2026, filed 23 Apr 2026.